FORM PTO-1449 (REV. 7-85) PATE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

EXAMINER

/Sahar Javanmard/

RTMENT OF COMMERCE

JC05 Rec'd PCT/PTO 17 JUN 2005 ATTY, DOG 10/539501 LR/G-3298 APPLICATION NO

Not Yet Known APPLICANT KRISCH ET AL. FILING DATE Herewith

Group

U.S. PATENT DOCUMENTS

0.0.1 74 241 0 0 0 0 0 0							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	4,935,429	6/19/90	Dackis et al.			
	AB	5,430,031	7/4/95	Brambilla et al.			
	AC	5,441,961	8/15/95	Cohen et al.			
	AD						
	AE						
	AF						
	AG						
-	АН						
	AI						
	AJ						
	AK						
	AL				1		

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	TRANSLATION YES NO	
AM	01/41763	6/14/01	wo					
AN								
AO								
AP								
AQ								

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

FYAMINE	R	DATE CONSIDERED 04/28/2008
4	ΑŤ	Zivin et al., "Antiparkinsonian Potential of Interaction of LEK.4829 with Bromocriptine", European Journal of Pharmacology, Vol. 349, No. 2-3, pp. 151-157 (1998).
A	AS	Glavan et al., "Modulation of Neuroleptic Activity of 9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8- aminomethylergoline bimaleinate (LEK-8829) by D1 Intrinsic Activity in Hemi-Parkinsonian Rates", Molecular Pharmacology, Vol. 61, No. 2, pp. 360-368 (2002).
A	AR	Milivojevic et al., "A Novel Ergoline Derivative LEX-0623 Attendades No. Suppl. 1, p. S55 (2003). of Cocaine-Seeking Behavior", Behavioural Pharmacology, Vol. 14, No. Suppl. 1, p. S55 (2003).

Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.